June 20, 2025

3 things you missed in government this week

ADA News is providing a roundup of government happenings you may have missed this week.

ADA News

June 19, 2025

Ropeginterferon Alfa-2b Outperforms Anagrelide as Second-Line Therapy for ET, Study Finds

Ropeginterferon alfa-2b demonstrated superior efficacy and safety compared with anagrelide as second-line therapy for patients with essential thrombocythemia (ET) who were intolerant or resistant to h...

The ASCO Post

June 18, 2025

NCCN Clinical Practice Guidelines in Oncology: 2025 Updates

The National Comprehensive Cancer Network (NCCN) released its first set of Clinical Practice Guidelines in Oncology (NCCN Guidelines®) in 1996, covering eight tumor types. Today, guidelines are availa...

The ASCO Post

June 17, 2025

Proposed Budget Cuts to Medicaid May Result in More Than 16,500 Medically Preventable Deaths Annually

The enactment of the proposed budget bill making its way through Congress, which includes major cuts to Medicaid, could increase the number of uninsured Americans by 7.6 million and the number of medi...

The ASCO Post

June 17, 2025

I Have Stage IV Lung Cancer and Still Consider Myself the Luckiest Man in the World

Although I have spent the past 2 decades of my medical career as a primary care physician, educator, and researcher in conditions that disproportionately affect people of Asian descent, including lung...

The ASCO Post

June 13, 2025

Weight Loss Drugs Show Promise for Heart Failure

ACC statement highlights semaglutide and tirzepatide as therapies associated with improved symptoms and functional capacity in patients with heart failure with preserved ejection fraction and obesity.

Conexiant

June 12, 2025

Navigating the Rapid Evolution of Dry Eye Treatment in Private Practice

Recent advances improve our ability to provide care if we integrate new developments and embrace change, writes optometrist Selina R. McGee

The Ophthalmologist

June 11, 2025

Checkmate 214 Presented by Toni Choueiri, MD.

Dr. Toni Choueiri shares groundbreaking 9-year results from the CHECKMATE-214 trial.

Dana-Farber

June 11, 2025

New Immunotherapy Trials Offer Hope to Previously Excluded Gynecologic Cancer Patients

Roswell Park Comprehensive Cancer Center offers gynecologic cancer patients multidisciplinary care from nationally recognized specialists who collaborate on personalized treatment plans.

Roswell Park Comprehensive Cancer Center